K
KPTI
Karyopharm Therapeutics Inc
9.10
-0.01-0.11%After Hours: 9.47 +0.37 +4.07%19:59 05/29 EDT
OPEN/PREV CLOSE9.28/9.10
TODAY RANGE8.99-9.88
VOL157.34K
MARKET CAP220.65M
52 WEEK RANGE3.650-10.99
AVG VOL (3M)926.05K
% TURNOVER0.69%
TURNOVER--
P/E (TTM)-0.6559
% RANGE9.78%
EPS(TTM)-14.8444
P/E(FORWARD)-2.3804
P/B-0.8262
BVPS-11.7834
DIVIDEND--
P/S1.221
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP209.04M
SHARES OUTSTANDING22.66M
NEXT EARNINGS08/10-08/14
FREE FLOAT21.47M
LOT SIZE1
EX-DATE02/26/2025
News
Press Releases
Financial Reports
Profile
TipRanks·05/20 04:38
Karyopharm (KPTI) Leans on SENTRY in Pivotal Call
Benzinga·05/19 12:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Simply Wall St·05/15 23:41
Karyopharm Therapeutics (KPTI) Quarterly Loss Deepens Reinforcing Bearish Profitability Concerns
TipRanks·05/15 15:26
Leerink Partners Sticks to Its Hold Rating for Karyopharm Therapeutics (KPTI)
TipRanks·05/15 11:48
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks·05/15 00:20
Karyopharm Earnings Call: Trial Wins, Cash Questions
Seeking Alpha·05/14 19:01
Karyopharm outlines $130M-$150M 2026 revenue outlook as it prepares mid-2026 XPORT-EC-042 readout
The Motley Fool·05/14 18:20
Karyopharm (KPTI) Q1 2026 Earnings Transcript
Benzinga·05/14 13:37
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.